AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34945205 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon expulsion test
Number of subjects: 16
Study 34945205 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-endoanal ultrasound
Number of subjects: 16
Study 34945205 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 16
Study 34945816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomically guided medication treatment
Number of subjects: 0
Study 34945816 — intervention group
Group type: COMPARATOR
Intervention: Standard medication treatment
Number of subjects: 0
Study 34946833 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34949129 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity exercise intervention
Number of subjects: 25
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: Any DMD exposure
Number of subjects: 35894
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: First-generation DMD exposure
Number of subjects: 35894
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: Second-generation DMD exposure
Number of subjects: 35894
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 35894
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod
Number of subjects: 35894
Study 34949130 — intervention group
Group type: COMPARATOR
Intervention: DMD exposure
Number of subjects: 35894
Study 34949190 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating EPAP settings to abolish EFL
Number of subjects: 26
Study 34949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (PSQI > 5)
Number of subjects: 295
Study 34949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleep quality (PSQI ≤ 5)
Number of subjects: 295
Study 34949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms and state anxiety
Number of subjects: 295
Study 34949542 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI scores
Number of subjects: 295
Study 34949542 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol types
Number of subjects: 295
Study 34949603 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) intervention, 3-5 sessions lasting up to 1 hour with a trained GSD facilitator.
Number of subjects: 224
Study 34949603 — intervention group
Group type: COMPARATOR
Intervention: Attention control group, 3-5 sessions lasting up to 1 hour with a communication-trained healthcare professional.
Number of subjects: 224
Study 34949603 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) intervention
Number of subjects: 224
Study 34949603 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 224
Study 34950083 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Family Holistic Health Intervention
Number of subjects: 0
Study 34950083 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34950101 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Induced Sleep Endoscopy
Number of subjects: 0
Study 34950101 — intervention group
Group type: COMPARATOR
Intervention: Natural Sleep Endoscopy
Number of subjects: 0
Study 34950502 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (TFM)
Number of subjects: 55
Study 34950688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake during radiotherapy
Number of subjects: 0
Study 34950688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary fiber intervention)
Number of subjects: 0
Study 34950880 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines (two doses, administered 12 weeks apart)
Number of subjects: 585
Study 34950880 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 or AZD1222 vaccines
Number of subjects: 585
Study 34950880 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior SARS-CoV-2 infection
Number of subjects: 585
Study 34950880 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD20 treatment
Number of subjects: 585
Study 34950913 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted MAP of 63 mmHg
Number of subjects: 0
Study 34950913 — intervention group
Group type: COMPARATOR
Intervention: Targeted MAP of 77 mmHg
Number of subjects: 0
Study 34950913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenation-target of 9-10 kPa
Number of subjects: 0
Study 34950913 — intervention group
Group type: COMPARATOR
Intervention: Oxygenation-target of 13-14 kPa
Number of subjects: 0
Study 34950913 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 34951386 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Number of subjects: 90
Study 34951522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 113
Study 34951594 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily incentives for self-weighing (loss incentive)
Number of subjects: 40
Study 34951594 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for adhering to GWG guidelines based on BMI category
Number of subjects: 40
Study 34951594 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for reaching physical activity goals
Number of subjects: 40
Study 34951594 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention satisfaction
Number of subjects: 40
Study 34951594 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention for follow-up data collection
Number of subjects: 40
Study 34951993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc in patients with nonalcoholic steatohepatitis (n = 19)
Number of subjects: 421
Study 34951993 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 candidate antifibrotics in organotypic ex vivo cultures of clinical fibrotic liver tissues (n = 78)
Number of subjects: 421
Study 34951993 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-protein serum protein-based surrogate FPS in compensated cirrhosis patients (n = 122)
Number of subjects: 421
Study 34951993 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gene FPS defined and validated in an independent NAFLD cohort
Number of subjects: 421
Study 34952000 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation (re-RT)
Number of subjects: 90
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength (maximal inspiratory pressure - MIP)
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle endurance (incremental threshold loading test)
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris muscle strength
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip muscle strength
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT) distance
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total energy expenditure
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels (number of steps)
Number of subjects: 27
Study 34952415 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL-PCD subscales scores)
Number of subjects: 27
Study 34952415 — intervention group
Group type: COMPARATOR
Intervention: MEP, shoulder abductor, elbow flexor muscle strength, active energy expenditure, physical activity duration, average metabolic equivalents, number of steps, lying time, sleep duration
Number of subjects: 27
Study 34952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory hold during patient-triggered assisted ventilation
Number of subjects: 0
Study 34952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressure measurement
Number of subjects: 0
Study 34952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Readable holds characteristics
Number of subjects: 0
Study 34952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreadable plateaus characteristics
Number of subjects: 0
Study 34952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular pressure computed from the hold
Number of subjects: 0
Study 34952560 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia during nighttime
Number of subjects: 21
Study 34952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrhythmias during nighttime
Number of subjects: 21
Study 34952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in hypoglycemia
Number of subjects: 21
Study 34952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic variability during nighttime
Number of subjects: 21
Study 34952679 — intervention group
Group type: EXPERIMENTAL
Intervention: RAdioPathomics Integrated preDiction System (RAPIDS)
Number of subjects: 1033
Study 34952679 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIDS
Number of subjects: 1033
Study 34952679 — intervention group
Group type: COMPARATOR
Intervention: Single-modality prediction models
Number of subjects: 1033
Study 34952879 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS plus CBIT
Number of subjects: 50
Study 34952879 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS plus CBIT
Number of subjects: 50
Study 34952881 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg per os, every night from anaesthesiologist preoperative consultation up to 5 days after surgery.
Number of subjects: 718
Study 34952881 — intervention group
Group type: COMPARATOR
Intervention: Placebo, every night from anaesthesiologist preoperative consultation up to 5 days after surgery.
Number of subjects: 718
Study 34952882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevent for Work Questionnaire (P4Wq)
Number of subjects: 115
Study 34952953 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 year
Number of subjects: 89
Study 34952962 — intervention group
Group type: EXPERIMENTAL
Intervention: No humidification (NoH)
Number of subjects: 20
Study 34952962 — intervention group
Group type: COMPARATOR
Intervention: HME (Heat and Moisture Exchanger)
Number of subjects: 20
Study 34952962 — intervention group
Group type: COMPARATOR
Intervention: HH34 (Heated Humidifier at 34°C)
Number of subjects: 20
Study 34952962 — intervention group
Group type: COMPARATOR
Intervention: HH37 (Heated Humidifier at 37°C)
Number of subjects: 20
Study 34953062 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular function assessed by echocardiography (RV-MPI and RV-FAC)
Number of subjects: 205
Study 34953062 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP ratio
Number of subjects: 205
Study 34953137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi™) alarm triggers
Number of subjects: 0
Study 34953137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous trends of ORi
Number of subjects: 0
Study 34953337 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel as an add-on therapy
Number of subjects: 483
Study 34953354 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS CDSS
Number of subjects: 25
Study 34953354 — intervention group
Group type: COMPARATOR
Intervention: Standard CPOE
Number of subjects: 25
Study 34953442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study 34953516 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34953600 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) followed by pembrolizumab 200 mg administered Q3W for eight cycles
Number of subjects: 30
Study 34953624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg daily and tremelimumab at 3 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Number of subjects: 27
Study 34953624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab at 6 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Number of subjects: 27
Study 34953624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab at 10 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Number of subjects: 27
Study 34953816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (2-11 mg/kg/day)
Number of subjects: 22
Study 34953816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IV dosing every 8-12 hours)
Number of subjects: 22
Study 34953816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IV and SC)
Number of subjects: 22
Study 34953816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IV therapy during hospitalization)
Number of subjects: 22
Study 34953862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab
Number of subjects: 0
Study 34953862 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab with obinutuzumab pretreatment (Gpt)
Number of subjects: 0
Study 34954052 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-007 (1-60 mg)
Number of subjects: 78
Study 34954052 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-007 (10-30 mg)
Number of subjects: 78
Study 34954052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 34954099 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus MobiMD app
Number of subjects: 300
Study 34954099 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 300
Study 34954217 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated women
Number of subjects: 165
Study 34954217 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 165
Study 34954325 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (≥ 150 min/week) in ARD patients (n = 494)
Number of subjects: 1095
Study 34954325 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (≥ 350 min/week) in ARD patients
Number of subjects: 1095
Study 34954325 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in non-ARD individuals
Number of subjects: 1095
Study 34954325 — intervention group
Group type: COMPARATOR
Intervention: Inactive ARD patients (n = 404)
Number of subjects: 1095
Study 34954325 — intervention group
Group type: COMPARATOR
Intervention: Inactive/sedentary ARD patients
Number of subjects: 1095
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric second-line treatment (triple therapy with amoxicillin and levofloxacin)
Number of subjects: 5055
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth)
Number of subjects: 5055
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day regimens using high doses of proton pump inhibitors with levofloxacin or moxifloxacin
Number of subjects: 5055
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 single capsule or levofloxacin-bismuth quadruple therapy
Number of subjects: 5055
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of adverse events
Number of subjects: 5055
Study 34954341 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule)
Number of subjects: 5055
Study 34954696 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPhos capacity of platelet mitochondria
Number of subjects: 111
Study 34955097 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Extremity Fugl-Meyer Assessment (FMA)
Number of subjects: 176
Study 34955097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System 10-Question Short Form (PROMIS-10)
Number of subjects: 176
Study 34955097 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of non-improvers
Number of subjects: 176
Study 34955167 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (≤10 days since intubation)
Number of subjects: 1740
Study 34955167 — intervention group
Group type: COMPARATOR
Intervention: Late tracheostomy (more than 10 days since intubation)
Number of subjects: 1740
Study 34955167 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Number of subjects: 1740
Study 34955335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in patients with higher MR severity
Number of subjects: 3878
Study 34955335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) and 1-year mortality in HFpEF
Number of subjects: 3878
Study 34955335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) and 1-year mortality in HFrEF
Number of subjects: 3878
Study 34955406 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells targeting CD123
Number of subjects: 0
Study 34955406 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cells targeting CD33
Number of subjects: 0
Study 34955406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual CAR T cells (CD123 and CD33)
Number of subjects: 0
Study 34955406 — intervention group
Group type: COMPARATOR
Intervention: Single CAR T cells (either CD123 or CD33)
Number of subjects: 0
Study 34955430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole-breast radiotherapy (40.05 Gy/15 fractions, without boost)
Number of subjects: 1325
Study 34955443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (35 mg) administered for 28 days
Number of subjects: 19
Study 34955641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 478
Study 34955641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 478
Study 34955641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study 34955811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disorders
Number of subjects: 0
Study 34955891 — intervention group
Group type: COMPARATOR
Intervention: 7-day-long antioxidative supplementation
Number of subjects: 18
Study 34955891 — intervention group
Group type: COMPARATOR
Intervention: Incremental cycling exercise (first exercise without supplementation as control)
Number of subjects: 18
Study 34955971 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Self-Compassion Intervention
Number of subjects: 0
Study 34955971 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study 34956078 — intervention group
Group type: EXPERIMENTAL
Intervention: TcPO2 stimulation test
Number of subjects: 107
Study 34956230 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and low-dose IL-2 (HDC/IL-2)
Number of subjects: 0
Study 34956230 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele of rs1049174
Number of subjects: 0
Study 34957004 — intervention group
Group type: EXPERIMENTAL
Intervention: LSTM prediction model based on patients' continual actigraphy monitoring
Number of subjects: 60
Study 34957004 — intervention group
Group type: COMPARATOR
Intervention: Standard Karnofsky Performance Status score
Number of subjects: 60
Study 34957480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular plasmid treatment
Number of subjects: 0
Study 34957480 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of plasmid
Number of subjects: 0
Study 34957480 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified plasmid for selection without antibiotic resistance
Number of subjects: 0
Study 34957526 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant nivolumab with ipilimumab
Number of subjects: 32
Study 34957526 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant nivolumab without ipilimumab
Number of subjects: 32
Study 34957654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg once daily for 5 days, followed by 7 mg for 5 days
Number of subjects: 55
Study 34957654 — intervention group
Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 55
Study 34958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz at left dorsolateral prefrontal cortex, 120% resting motor threshold)
Number of subjects: 26
Study 34958013 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 26
Study 34958013 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 26
Study 34958258 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedication Reviews
Number of subjects: 0
Study 34958346 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempil-Ziv Complexity (LZC)
Number of subjects: 89
Study 34958346 — intervention group
Group type: EXPERIMENTAL
Intervention: LZC normalized (LZCn)
Number of subjects: 89
Study 34958346 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium diagnosis
Number of subjects: 89
Study 34958346 — intervention group
Group type: EXPERIMENTAL
Intervention: LZCn
Number of subjects: 89
Study 34958346 — intervention group
Group type: EXPERIMENTAL
Intervention: LZC
Number of subjects: 89
Study 34958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake from fruits
Number of subjects: 343
Study 34958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate intake from cooked grains
Number of subjects: 343
Study 34958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet dry weight
Number of subjects: 343
Study 34958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Grams of carbohydrates
Number of subjects: 343
Study 34958387 — intervention group
Group type: EXPERIMENTAL
Intervention: Grams of fiber
Number of subjects: 343
Study 34958808 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BCG scar
Number of subjects: 10598
Study 34958928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg
Number of subjects: 78
Study 34959133 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker concentrations (GFAP, NFL, NSE, S100B, t-tau, UCH-L1) measured <24 hours post-injury.
Number of subjects: 2869
Study 34959133 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker concentrations (GFAP, S100B, t-tau)
Number of subjects: 2869
Study 34959133 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker concentrations (GFAP, NFL, NSE, t-tau, UCH-L1)
Number of subjects: 2869